Literature DB >> 16822286

The post-thrombotic syndrome: progress and pitfalls.

Susan R Kahn1.   

Abstract

The post-thrombotic syndrome (PTS) develops in up to one half of patients after symptomatic deep venous thrombosis (DVT) and is the most common complication of DVT. Typical features of PTS include chronic pain, swelling, heaviness, oedema and skin changes in the affected limb. In severe cases, venous ulcers may develop. The frequency of PTS is likely to be reduced by preventing DVT with the use of effective thromboprophylaxis in high-risk patients and settings and by minimising the risk of ipsilateral DVT recurrence. Use of compression stockings for 2 years after DVT appears to reduce the incidence and severity of PTS but issues remain regarding their use and effectiveness. Future research should focus on elucidating the pathophysiology and risk factors for PTS, assessing the safety and effectiveness of catheter-directed thrombolysis to prevent PTS and evaluating the optimal use of compression stockings to prevent and treat PTS. In addition, new therapies to treat PTS should be sought and evaluated.

Entities:  

Mesh:

Year:  2006        PMID: 16822286     DOI: 10.1111/j.1365-2141.2006.06200.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  35 in total

Review 1.  [Medical compression therapy of the extremities with medical compression stockings (MCS), phlebological compression bandages (PCB), and medical adaptive compression systems (MAC) : S2k guideline of the German Phlebology Society (DGP) in cooperation with the following professional associations: DDG, DGA, DGG, GDL, DGL, BVP. German version].

Authors:  E Rabe; E Földi; H Gerlach; M Jünger; G Lulay; A Miller; K Protz; S Reich-Schupke; T Schwarz; M Stücker; E Valesky; F Pannier
Journal:  Hautarzt       Date:  2021-02       Impact factor: 0.751

Review 2.  Comprehensive evaluation of patients suspected with deep vein thrombosis using indirect CT venography with multi-detector row technology: from protocol to interpretation.

Authors:  Yen-Ting Lin; I-Chen Tsai; Wei-Lin Tsai; Min-Chi Chen; Pao-Chun Lin; Si-Wa Chan; Clayton Chi-Chang Chen
Journal:  Int J Cardiovasc Imaging       Date:  2010-08-25       Impact factor: 2.357

3.  Low-dose systemic thrombolytic therapy for deep vein thrombosis in pediatric patients.

Authors:  Sarah E Leary; Virginia L Harrod; Pedro A de Alarcon; Ulrike M Reiss
Journal:  J Pediatr Hematol Oncol       Date:  2010-03       Impact factor: 1.289

4.  SEOM guidelines on thrombosis in cancer patients.

Authors:  Andrés J Muñoz; Nuria Viñolas; Ricardo Cubedo; Dolores Isla
Journal:  Clin Transl Oncol       Date:  2011-08       Impact factor: 3.405

5.  Life quality changes within 26 month after the non-surgical treatment in patients with deep vein thrombosis.

Authors:  Ye Tian; Jun Luo; Qiang Cao; Chao Bai; Sairike Magovia
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 6.  Overview of venous thromboembolism.

Authors:  José Ignacio Abad Rico; Juan Vicente Llau Pitarch; Eduardo Rocha
Journal:  Drugs       Date:  2010-12-14       Impact factor: 9.546

Review 7.  Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization.

Authors:  Aniek Ag Zee; Kelly van Lieshout; Maaike van der Heide; Loes Janssen; Heinrich Mj Janzing
Journal:  Cochrane Database Syst Rev       Date:  2017-08-06

Review 8.  Thrombolysis for acute deep vein thrombosis.

Authors:  Lorna Watson; Cathryn Broderick; Matthew P Armon
Journal:  Cochrane Database Syst Rev       Date:  2016-11-10

9.  Compression stockings to prevent post-thrombotic syndrome: a role for anticoagulation clinics?

Authors:  Ann K Wittkowsky; Edith A Nutescu; Emily Beth Devine
Journal:  J Thromb Thrombolysis       Date:  2007-11-30       Impact factor: 2.300

Review 10.  Contemporary issues in the prevention and management of postthrombotic syndrome.

Authors:  Sara R Vazquez; Andrew Freeman; Ryan C VanWoerkom; Matthew T Rondina
Journal:  Ann Pharmacother       Date:  2009-09-08       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.